New Deal
Bihua Chen
CEO at CORMORANT ASSET MANAGEMENT
Investor
Deal Bio
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.
Expertise (36)
Key Relationships
Announcement Date
Deal Value
ERASCA
Arch Venture Partners
£161m
22 dealmakers
Atea Pharmaceuticals
Ally Bridge Group
£175m
27 dealmakers
Greenlight Biosciences
Mls Capital Fund Ii
£81m
12 dealmakers
I-MAB
Hillhouse Capital Group
£315m
33 dealmakers
Velosbio
Cormorant Asset Management
£105m
16 dealmakers
Element Science
The Invus Group
£114m
13 dealmakers
BIOATLA
Soleus Capital
£55m
14 dealmakers
VECTIVBIO
£84m
35 dealmakers
Miragen Therapeutics
VENROCK
£70m
19 dealmakers
Neurogene
Casdin Capital
£85m
Visen Pharmaceuticals
Orbimed Pe
£111m
Centessa Pharmaceuticals
Janus Henderson Investors
£179m
Artiva Biotherapeutics
Acuta Capital
value n/a
Epimab Biotherapeutics
Octagon Investments
£86m
Tango Therapeutics
£257m
32 dealmakers
Icosavax
Sanofi Ventures
£71m
Gh Research
Deerfield Management Company
£91m
20 dealmakers
Elpiscience Biopharmaceutical
£74m
10 dealmakers
Numab Therapeutics
Novo Holdings
£78m
11 dealmakers
Nikang Therapeutics
Surveyor Capital
£141m
29 dealmakers
Prime Medicine
T. Rowe Price Group
£227m
17 dealmakers
Umoja Biopharma
£148m
Strata Oncology
Baird Capital
£64m
Xeraya Capital
£866m
39 dealmakers
SHOUTI
£72m
Chroma Medicine
Atlas Venture
£93m
Moonlake Immunotherapeutics
Bvf Partners
£169m
44 dealmakers
Korro Bio
Ventus Therapeutics
Andreessen Horowitz
£103m
Tessera Therapeutics
Abu Dhabi Investment Authority (adia)
£230m
26 dealmakers
Moma Therapeutics
Rock Springs Capital
£121m
Jenavalve Technology
Gimv
18 dealmakers
ENSOMA
Arix Bioscience
£108m
BIVACOR
£14m
5 dealmakers
Onkure Therapeutics
£43m
15 dealmakers